All News

The European Parliament calls for an ‘internationalisation strategy’ to create a single set of rules for small companies - and unleash entrepreneurial potential

Commissioners announce effort to mobilise greener and more efficient transport for Europe

After months of shadow-boxing, EU leaders have scheduled a few key meetings in November to decide how much and how Horizon 2020 money will be spent. A special Science|Business report examines the proposals on the table.

Current weak economic recovery will likely lead to continued sluggish growth in R&D spending by firms, says a new OECD report

The London 2012 tingle is receding, but the legacy should be about more than finding a new use for the Olympic Stadium. By Nuala Moran.

A group led by the University of Manchester will focus on materials across a variety of energy and industrial applications

The public should be given the opportunity to take a direct role in supporting innovative start-ups, says Steven Bates, chief executive of the UK BioIndustry Association

While northern and western European countries cut it in the top ranks of this year’s Global Competitiveness Report, those in the south are losing ground

One of the biggest barriers to commercialising breakthrough research is getting scientists to come forward with their ideas. Rolling out the role models can help

Top EU businesses expect their investments in research and development to grow by an average of 4 percent annually over the period 2012 to 2014

Spin-outs from TU Berlin are multiplying despite the tough economic climate. This success holds lessons for other universities on how to promote entrepreneurship

New evidence from Italy shows that - contrary to the accepted view - academics who become entrepreneurs don’t publish less. This is an important message for universities which fear encouraging start-ups will harm their research, says Michael Kenward

MEP Malcolm Harbour spearheads a growing movement in Brussels to get government agencies spending more of their budgets on innovation - especially from small companies

At the fourth time of asking, the European Medicines Agency is recommending approval of Glybera, opening up a new era in the treatment of rare diseases, and unlocking the wider potential of gene therapy

Recent progress has been encouraging, but MEPs’ decision not to vote on the single European Patent leaves innovative businesses without the historic breakthrough they so desperately need, says Jonathan Zuck